MET-CAR.CD28ζ

**MET-CAR.CD28ζ** is an investigational autologous chimeric antigen receptor T cell therapy specifically engineered to target the MET tyrosine kinase receptor, which is frequently overexpressed in tumors such as hepatocellular carcinoma (HCC). The CAR construct incorporates an extracellular antibody-derived domain recognizing MET and an intracellular co-stimulatory signaling domain from CD28, fused to the CD3ζ chain. This configuration enables robust T-cell activation, cytotoxic cytokine release, and targeted lysis of MET-positive tumor cells. MET-CAR.CD28ζ demonstrates potent anti-tumor effects in vitro and in vivo, showing superior efficacy to comparable CARs with 4-1BBζ co-stimulatory domains, although it is associated with higher levels of T-cell exhaustion. The therapy is under evaluation for patients whose tumors exhibit MET overexpression, independent of MET signaling activation[2]. Initial studies and preclinical evidence suggest enhanced cytokine production and cytotoxicity, but challenges remain regarding persistence and long-term efficacy due to potential CAR-T cell exhaustion.

Brand names

MET-CAR.CD28ζ

Other names

MET-specific CAR-T cells with CD28ζ co-stimulatory domain